6911-88-2

Usage

Uses

Used in Pharmaceutical Industry:
2-bromo-N-methyl-4-nitroaniline is used as a chemical intermediate for the synthesis of various pharmaceuticals. Its unique structure allows it to be a key component in the development of new drugs, contributing to the advancement of medicinal chemistry.
Used in Dye Industry:
In the dye industry, 2-bromo-N-methyl-4-nitroaniline is utilized as an intermediate in the production of dyes. Its chemical properties enable it to be a vital part of the formulation of various colorants used in different applications, such as textiles, plastics, and printing inks.

Upstream product

• 100-15-2 N-methyl(p-nitroaniline) 
• 7726-95-6 bromine 
• 100-00-5 4-chlorobenzonitrile 
• 100-23-2 N,N-Dimethyl-4-nitroaniline 
• 64230-23-5 2-bromo-4-nitro-N,N-dimethylaniline 
• 860533-10-4 2-bromo-N-methyl-4-nitro-N-nitroso-aniline 

Downstream Products

• 98273-68-8 2,6-dibromo-N-methyl-4-nitro-aniline 
• 860533-09-1 2-bromo-N-methyl-4,6,N-trinitro-aniline 
• 952664-80-1 [2-(3,3-dimethyl-but-1-ynyl)-4-nitro-phenyl]-methyl-amine 
• 952664-81-2 2-tert-butyl-1-methyl-5-nitro-1H-indole 
• 1332527-89-5 C₁₁H₁₀N₂O₃ 
• 1332527-56-6 4-{[3-(4-dimethylamino-3-furan-2-ylphenylsulfamoyl)benzenesulfonylamino]methyl}piperidine-1-carboxylic acid tert-butyl ester 
• 158722-73-7 C₁₂H₁₄N₂O 
• 158722-72-6 C₁₂H₁₂N₂O₃ 
• 1332527-87-3 4-{[3-(4-dimethylamino-3-furan-2-ylphenylsulfamoyl)benzenesulfonylamino]methyl}-1-butyrylpiperidine 
• 1332527-86-2 4-{[3-(4-dimethylamino-3-furan-2-ylphenylsulfamoyl)benzenesulfonylamino]methyl}piperidine 

Relevant academic research and scientific papers

Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

TGF-beta SIGNAL TRANSDUCTION INHIBITOR

The present invention provides a compound represented by the following formula (I) or a physiologically acceptable salt thereof, and use thereof for the prophylaxis or treatment of TGF-β-related diseases: wherein Y is a hydrogen atom and the like; R2 is and the like; R3 is —NR8—R9— and the like; R4, R5, R6 and R7 are the same or different and each is a hydrogen atom and the like; and X is and the like.

Modulators of ATP-binding cassette transporters

Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.